19.7.2021 – Asceneuron appoints prominent healthcare leader Catherine Moukheibir to its board of directors
Based at EPFL Innovation Park, Asceneuron is a clinical-stage company dedicated to targeting the root cause of neurodegenerative diseases.
The startup recently welcomed Catherine Moukheibir to its Board of Directors. Catherine is a highly respected healthcare executive with extensive experience over the last 30 years of leadership in finance, capital markets and life sciences. She has previously worked as a Chairman, Non-Executive Director and Chief Executive Officer in the biotech and pharmaceutical sectors, successfully raising private and public capital as well as overseeing several major licensing deals and acquisitions.
Read more on Ascneuron webpage